Colchicine, the treatment of choice for prophylaxis of FMF flares and prevention of amyloidosis has been shown to be a more effective treatment for PFAPA flare prophylaxis in those with FMF gene mutations (19); this may partially explain the differences in the response to colchicine therapy between the FH− and FH+ groups. This evidence concerns the gene MEFV and amyloidosis.